SSS67
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 24, 2026
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion
(clinicaltrials.gov)
- P1 | N=52 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
New P1 trial
1 to 1
Of
1
Go to page
1